NewCardio Names Ihor Gussak, M.D., Ph.D., FACC Chief Medical Officer

Former VP, Global Medical Affairs at eResearchTechnology, Inc.,
Adds Significant Experience with Major Pharmaceutical Companies,
Academia, CROs, and Central ECG Core Laboratories
SANTA CLARA, Calif.--(Business Wire)--
NewCardio, Inc. (OTCBB: NWCI), a cardiac diagnostic and services
company, announced today that Ihor Gussak, M.D., Ph.D., FACC,
world-recognized expert in electrocardiology and cardiac safety, has
joined the Company as its new Chief Medical Officer and Vice
President, effective immediately.

Dr. Gussak joins NewCardio from Boehringer Ingelheim
Pharmaceuticals, where he held a senior executive role for the past
year. Previously, Dr. Gussak served 5 years as Vice President, Global
Medical Affairs for eResearchTechnology, Inc., and held a key
executive position with Aventis Pharmaceuticals Inc, employed by Mayo
Clinic, and the ECG Core Lab at St. Louis University Health Sciences
Center. He has participated in management of many clinical trials,
consulted with many contract research organizations (CROs), and is
credited with major contributions and publications in the field of
cardiovascular medicine.

Dr. Gussak received his M.D. from Tartu University School of
Medicine (Tartu, Estonia), and his PhD in Medical Sciences/Cardiac
Electrophysiology (Acute Myocardial Ischemia in Clinic and
Experiments) from the National Center for Surgical Treatment of Severe
Cardiac Rhythm Disturbance and Cardiac Pacing (Kaunas, Lithuania). He
received further training in the US at Mayo Clinic and the ECG Core
Lab at St. Louis University Health Sciences Center. At present, he is
Clinical Professor of Medicine at University of Medicine and
Dentistry-Robert Wood Johnson Medical School, and Executive Editor,
Journal of Electrocardiology, a position he has held since 2004.

Dr. Gussak's primary scientific interests are in clinical
electrocardiography and cardiac electrophysiology, including cardiac
safety, cardiac arrhythmias, sudden cardiac death, Brugada syndrome,
and Short QT syndrome. He has published several textbooks and numerous
peer-reviewed articles on these and other subjects in clinical
cardiology. His most recent published book, Electrical Diseases of the
Heart and Sudden Cardiac Death: Genetics, Mechanisms, Treatment,
Prevention (Ihor Gussak and Charles Antzelevitch, editors) was
recently praised in the New England Journal of Medicine (359:103, July
3, 2008) as "a thoughtful and thorough review ... a definitive text
that will be useful to all who have an interest in cardiac
arrhythmia."

Dr. Gussak is a Fellow of the American College of Cardiology, and
serves on the Clinical Cardiology Council of the American Heart
Association. He is a member of the American Academy of Pharmaceutical
Physicians, the International Cardiac Electrophysiology Society, the
International Society for Holter and Noninvasive Electrocardiology,
the Drug Information Association, and the International Scientific
Committee on Arrhythmogenic Right Ventricular
Dysplasia-Cardiomyopathy.

Branislav Vajdic, Ph.D., President and Chief Executive Officer,
commented, "Dr. Gussak is a recognized leader around the world in the
area of Clinical Trials and Cardiac Safety. We are exceptionally
pleased to add him as a senior member of our management team and look
forward to benefiting from his expertise and leadership. Dr. Gussak's
reputation within the industry, and relationships with leading
pharmaceutical companies, as well as some of the top CROs in the
world, and his efforts in clinical and academic research related to
the electrical activity of the heart and ECG methodology should prove
invaluable as we commercialize our QTinno(TM) product and further
develop the 3D ECG platform technology which underlies this lead
product. NewCardio's capabilities to positively impact clinical
trials, pharmaceutical research, and both the acute and long-term care
of patients with heart conditions should be enhanced by Dr. Gussak's
contributions."

Dr. Gussak added, "I believe NewCardio's 3D ECG platform
technology possesses unique promise areas as a diagnostic tool in a
broad range of cardiovascular diseases. For more than 100 years, the
ECG has been the standard tool for evaluating disorders of cardiac
electrical activity, but until now the technology has not been
significantly improved. NewCardio's 3D ECG technology offers the
potential to provide more diagnostic information, more rapid and
reproducible ECG readings, and more accurate and cost-effective
clinical trials. I am truly excited to be part of the development of
this technology."

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company focused on
the development of a proprietary platform technology to provide higher
accuracy to, and increase the value of, the standard 12-lead
electrocardiogram (ECG). NewCardio's development-stage software and
hardware products and services are intended to improve the diagnosis
and monitoring of cardiovascular disease (CVD), as well as cardiac
safety assessment of drugs under development. NewCardio's
three-dimensional ECG platform is designed to reduce the time and
expense involved in assessing cardiac status while increasing the
ability to diagnose clinically significant conditions which were
previously difficult to detect. For more information, visit
www.newcardio.com.

Forward-Looking Statements

This press release contains forward-looking statements.
Forward-looking statements include, but are not limited to, statements
that express our intentions, beliefs, expectations, strategies,
predictions or any other statements relating to our future activities
or other future events or conditions. These statements are based on
current expectations, estimates and projections about our business
based on currently available information and assumptions made by
management. Although we believe that the assumptions on which the
forward-looking statements contained herein are based are reasonable,
any of those assumptions could prove to be inaccurate given the
inherent uncertainties as to the occurrence or nonoccurrence of future
events. These statements are not guarantees of future performance and
involve risks and uncertainties that are difficult to predict.
Therefore, actual outcomes and results may, and are likely to, differ
materially from what is expressed or forecasted in the forward-looking
statements due to numerous factors, including the potential risks and
uncertainties set forth in Item 1A of our Annual Report on Form 10-K/A
(No. 1) for the year ended December 31, 2007 and relate to our
business plan, our business strategy, development of our proprietary
technology platform and our products, timing of such development,
timing and results of clinical trials, level and timing of FDA
regulatory clearance or review, market acceptance of our products,
protection of our intellectual property, implementation of our
strategic, operating and people initiatives, benefits to be derived
from personnel and directors, ability to commercialize our products,
our assumptions regarding cash flow from operations and cash on-hand,
the amount and timing of operating costs and capital expenditures
relating to the expansion of our business, operations and
infrastructure, implementation of marketing programs, our key
agreements and strategic alliances, our ability to obtain additional
capital as, and when, needed, and on acceptable terms and general
economic conditions specific to our industry, any of which could
impact sales, costs and expenses and/or planned strategies and timing.
We assume no obligation to, and do not currently intend to, update
these forward-looking statements.

To join our email distribution, please click this link:
http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0

Hayden Communications, Inc.
Jeff Stanlis, 602-476-1821
jeff@haydenir.com

Copyright Business Wire 2008